Literature DB >> 18404795

Two-dimensional electrophoresis and immunohistochemical study of calreticulin in colorectal adenocarcinoma and mirror biopsies.

K Vougas1, E Gaitanarou, E Marinos, C Kittas, I E Voloudakis-Baltatzis.   

Abstract

PURPOSE: The purpose of this study was to analyse the polypeptide patterns of colorectal adenocarcinomas and mirror biopsies and to investigate the expression of calreticulin and the relationship of this chaperon to colon cancer.
MATERIALS AND METHODS: The investigation was carried out on 21 adenocarcinomas and 21 mirror biopsies using high-resolution two-dimensional (2D) electrophoresis and immunohistochemical PAP method.
RESULTS: 2D electrophoresis revealed several polypeptide patterns that were shown to be upregulated in colorectal adenocarcinomas compared to their mirror biopsies. One polypeptide spot being upregulated in colorectal adenocarcinoma, turned out to be calreticulin. The overexpression of calreticulin was confirmed by further examination in immunohistochemical level.
CONCLUSION: Calreticulin was found overexpressed in colon cancer tissues as compared to the corresponding mirror biopsy tissues. The overexpression was particularly intense to high-malignancy tissues and particularly in the poorly differentiated regions of the tissue. Calreticulin showed a direct relationship to the disease stage, a fact strongly indicating that the functional role of calreticulin is directly associated with tumor growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404795

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  8 in total

1.  Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer.

Authors:  Rui-Qing Peng; Ying-Bo Chen; Ya Ding; Rong Zhang; Xing Zhang; Xing-Juan Yu; Zhi-Wei Zhou; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  Calreticulin nuclear translocalization alleviates CaM/CaMKII/CREB signaling pathway to enhance chemosensitivity in HDAC inhibitor-resistant hepatocellular carcinoma cells.

Authors:  Yi-Sheng Liu; Yu-Chun Chang; Wei-Wen Kuo; Ming-Cheng Chen; Tso-Fu Wang; Tung-Sheng Chen; Yueh-Min Lin; Chi-Cheng Li; Po-Hsiang Liao; Chih-Yang Huang
Journal:  Aging (Albany NY)       Date:  2022-06-20       Impact factor: 5.955

Review 3.  Calreticulin and cancer.

Authors:  Mohammadreza Zamanian; Abhi Veerakumarasivam; Syahril Abdullah; Rozita Rosli
Journal:  Pathol Oncol Res       Date:  2013-02-08       Impact factor: 3.201

4.  Calreticulin is a B cell molecular target in some gastrointestinal malignancies.

Authors:  A Pekáriková; D Sánchez; L Palová-Jelínková; M Simsová; Z Benes; I Hoffmanová; P Drastich; I Janatková; T Mothes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2009-12-17       Impact factor: 4.330

5.  Calreticulin mediates an invasive breast cancer phenotype through the transcriptional dysregulation of p53 and MAPK pathways.

Authors:  Mohammadreza Zamanian; Lama Abdel Qader Hamadneh; Abhi Veerakumarasivam; Sabariah Abdul Rahman; Shamarina Shohaimi; Rozita Rosli
Journal:  Cancer Cell Int       Date:  2016-07-13       Impact factor: 5.722

6.  Bioinformatics analysis for the role of CALR in human cancers.

Authors:  Yijun Li; Xiaoxu Liu; Heyan Chen; Peiling Xie; Rulan Ma; Jianjun He; Huimin Zhang
Journal:  PLoS One       Date:  2021-12-15       Impact factor: 3.240

7.  Calreticulin promotes EMT in pancreatic cancer via mediating Ca2+ dependent acute and chronic endoplasmic reticulum stress.

Authors:  Weiwei Sheng; Guosen Wang; Jingtong Tang; Xiaoyang Shi; Rongxian Cao; Jian Sun; Yi Heng Lin; Chao Jia; Chuanping Chen; Jianping Zhou; Ming Dong
Journal:  J Exp Clin Cancer Res       Date:  2020-10-07

Review 8.  The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.

Authors:  Tanja Belčič Mikič; Tadej Pajič; Samo Zver; Matjaž Sever
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.